NCT00248157View on ClinicalTrials.gov

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

PHASE3TerminatedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Diabetic Retinopathy
Interventions
DRUG

Octreotide acetate in microspheres

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00248157 - Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter